The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study.
The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study.
复制标题
澳大利亚昆士兰州肾移植受者患皮肤癌的风险。
作者：
J. Bavinck;David R. Hardie;A. Green;Suzanne Cutmore;Andrew Macnaught;B. O’Sullivan;V. Siskind;F. J. Woude;I. Hardie
对澳大利亚昆士兰州1098例肾移植受者进行了一项长期的回顾性随访研究，以评估皮肤癌的风险。在一个亚组中，我们还评估了免疫抑制治疗对皮肤癌发生风险的影响：环孢素单独或与强的松龙联合；硫唑嘌呤单独或与强的松龙联合；环孢素和硫唑嘌呤联合或不联合强的松龙。通过生命表分析计算，皮肤癌的累积发病率从免疫抑制1年后的7%逐渐增加到11年后的45%，并在免疫抑制20年后增加到70%。对长期服用环孢素A或硫唑嘌呤(分别使用或不使用强的松龙)的患者和联合使用环孢素和硫唑嘌呤(使用或不使用强的松龙)的患者患皮肤癌的风险进行了多因素分析，结果显示两组之间没有差异。我们的结论是，与免疫抑制相关的皮肤癌风险增加可能与所使用的药物(S)无关，而是免疫抑制本身的结果。
A long-term retrospective follow-up study was performed to evaluate the risk of skin cancer in 1098 renal transplant recipients in Queensland, Australia. In a subgroup, we also assessed the influence of immunosuppressive therapy on the risk of developing skin cancer: cyclosporine alone or in combination with prednisolone; azathioprine alone or in combination with prednisolone; or the combination of cyclosporine and azathioprine with or without prednisolone. The cumulative incidence of developing skin cancer, calculated by life table analysis, increased progressively from 7% after 1 year of immunosuppression to 45% after 11 years and to 70% after 20 years of immunosuppression. Multivariate analysis in a subgroup comparing the risk of developing skin cancer in patients on either long-term cyclosporine or azathioprine (each with or without prednisolone) and in patients on the combination of cyclosporine and azathioprine (with or with- out prednisolone) showed no differences between the groups. We conclude that it is likely that the increased risk of skin cancer associated with immunosuppression is independent of the agent(s) used and is a result of the immunosuppression per se.
环孢素治疗和非环孢素治疗的成人原发性同种异体肾移植受者中的新生癌症。
影响因子：
2.1
作者：
Gruber,SA;Gillingham,K;Sothern,RB;Stephanian,E;Matas,AJ;Dunn,DL
通讯作者：
Dunn,DL